The US has long been the leader in research and development in oncology, but homegrown Chinese drugmakers have jumped one hurdle after another in making a name for themselves. Now, the Chinese government is erecting new hurdles for its native industry to leap, and — at least for now — it’s putting a slight chill on the field.
The Chinese health authority NMPA’s Center for Drug Evaluation released new guidance on oncology R&D late last week, offering a new gold standard for how homegrown drugmakers should determine clinical efficacy amid a booming field for drug innovation, according to draft documents…
